Topic

All

16
Feb
2018

All-Star Lineup for Boston Cancer Summit, March 7: Novartis, J&J, Third Rock, Atlas

Timmerman Report is bringing together major East Coast cancer R&D players for an intimate half-day event on March 7: the Boston Cancer Summit. Join an all-star gathering of pharma executives, hot startups, and VCs making things happen in the treatment and diagnosis of cancer.  Tickets are sold out. The conference will be at Sanofi Genzyme’s flagship building in the heart of Kendall Square....
Read More
15
Feb
2018

Mingle in Seattle with Genentech, Celgene, OrbiMed, 5AM & More, March 5

Exclusive Event, Powerhouse Lineup: Seattle Cancer Summit Seattle biotech events don’t get any better than this. Timmerman Report is bringing together major West Coast players for an intimate half-day event on March 5: the Seattle Cancer Summit. Tickets are limited and going fast. And all proceeds go to the Fred Hutchinson Cancer Research Center, as part of my Everest Climb to Fight...
Read More
14
Feb
2018

Building a Cancer R&D Engine To Last: David Schenkein on The Long Run

Today’s guest on The Long Run podcast is David Schenkein. He’s the CEO of Cambridge, Mass.-based Agios Pharmaceuticals. Agios was founded a decade ago on the then-provocative idea of fighting cancer via new understanding of metabolic pathways that get hijacked by cancer cells. The company has grown up quite a bit since. It went from concept to new chemical entities...
Read More
5
Feb
2018

The Caveman’s Guide to Productivity

One TR subscriber already knew about some of my quirks: he and I rode in a van together for 26 hours straight to do the 200-mile Ragnar Reach the Beach Relay in New Hampshire. But when I published last month’s column detailing my Everest training, he wanted to know more. “I study performance pretty carefully, so all these kinds of questions fascinate...
Read More
31
Jan
2018

Big Idea, Big Money, Big Skepticism: The Long Run Podcast With Stephane Bancel

Today’s guest on The Long Run is Stephane Bancel. He’s the CEO of Cambridge, Mass.-based Moderna Therapeutics. The company, and the man at the helm, are somewhat controversial. Google Bancel’s name, and the ‘People Also Search For’ window shows famous entrepreneurs like Jeff Bezos, Elon Musk…and Elizabeth Holmes of Theranos infamy. Each situation for those entrepreneurs is different, and comparisons...
Read More
29
Jan
2018

The Boston Cancer Summit & Seattle Cancer Summit. Two Can’t-Miss Events

Cancer wasn’t that exciting to write about when I started 15 years ago. It is now. Survival rates for several forms of cancer are going in the right direction. Immunotherapy, targeted therapy, new information on genes and proteins that redefine the molecular nature of malignancy? It’s coming together. The science is bursting with creativity, and moving fast. I’m thinking and...
Read More
17
Jan
2018

Getting a Seat at the Table: The Long Run Podcast With Abbie Celniker

Today’s guest on The Long Run is Abbie Celniker. She’s a partner with Third Rock Ventures, and the chair of MassBio, the biotech trade association in Massachusetts. These are two major positions of industry influence. In this episode, I asked Celniker a lot of questions about how her career path ended up here. We also talked about the changing of...
Read More
3
Jan
2018

Scholar Rock, After a Year on Pause, Snags $47M to Take New Tack Against SMA

Spinal muscular atrophy is one of the ongoing success stories in biotech. But that doesn’t mean the story’s over. Cambridge, Mass.-based Biogen won a first-of-its-kind FDA approval a year ago with a new antisense oligonucleotide, licensed from Ionis Pharmaceuticals. The drug, nusinersen (Spinraza), allows kids with a crippling disease to produce greater amounts of the SMN protein they need to...
Read More